SOURCE: Revolutions Medical Corp.

Revolutions Medical Corp.

December 03, 2009 16:00 ET

RevMed Successfully Introduces MRI Product Suite at Radiology Society of North America Conference

CHARLESTON, SC--(Marketwire - December 3, 2009) - Revolutions Medical Corporation ("RevMed" or the "Company") (OTCBB: RMCP), producers of the RevVac safety syringe, RevColor, RevDisplay and Rev3D MRI Technology, today announced that it introduced its proprietary suite of MRI software products at this week's Radiology Society of North America (RSNA) annual meeting with great success. Radiologists and universities world-wide received presentations at the RMCP booth. A number of these contacts could play an important role in the Company's ongoing efforts to clinically validate specific applications of its MRI tools prior to the 2010 commercial launch.

"I could not be more pleased about the overwhelming interest that our MRI tools generated at this first introduction of our technology, and moreover at the premier imaging conference in the world," stated RevMed CEO Ron Wheet. "Introducing our proprietary MRI product offering at this conference was a dramatic step forward to commercialization in 2010. Radiologists immediately understood the utility of our products. Universities, OEM and VAR providers requested follow-up discussions regarding clinical collaboration. They also want to explore delivery options, i.e. embedding our product content into their existing commercially available products. Timely hot topics at the show included MRI analysis in breast disease, and brain abnormalities such as the depth of injury in concussion (as reported by the NFL); these led to discussions as to how our unique MRI color software would aid in image analysis, thereby enhancing diagnostic confidence in an entirely different way."

Tom O'Brien, RevMed President and participant in his 29th RSNA, stated, "Our CTO Rich Theriault and I spent several days meeting with a number of companies that ranged from MRI system providers to PACS/value-added resellers. We were excited to find that our MRI tools were both 'state of the art' and unique. Just as important, our business model of offering our products through a web-based SAS (software-as-service) is ahead of the curve. We are going to deliver our products via a web browser model right from the beginning, giving us a decided commercial advantage as vendors rush to add valuable content (like our proprietary MRI software tools) to their existing products. It is clear that this is the future direction of the medical imaging industry."

To be added to the RevMed investor email list, please email with RMCP in the subject line.

About Revolutions Medical Corporation (

RevMed's products include the RevVac safety syringe (FDA Approved), safety blood drawing device and safety IV catheter. RevMed also provides RevColor, RevDisplay and Rev3D -- software solutions and proprietary tools that are compatible with standard MRIs and standard PACS. The software suite's functionality includes sorting of images, color, 3D and automatic segmentation of images.

Investor Resource Center

Fact Sheet:

CEO Ron Wheet Audio Interview:

RevVac Demo Video:


The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Contact Information